Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | XBP1 | P17861 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | KIF11 | P52732 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.58 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.58 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.58 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28911724 | 0.87 | EPHX2 (0.50) | NR1H4EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13651401 | 0.87 | EPHX2 (0.50) | NR1H4EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13756246 | 0.84 | MAPT (0.81) | NR1H4EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2730172 | 0.84 | MAPT (0.81) | NR1H4EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14076379 | 0.83 | NR1H4 (0.61) | NR1H4EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4638258 | 0.83 | NR1H4 (0.65) | NR1H4EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL785306 | 0.83 | NR1H4 (0.66) | NR1H4EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2090688 | 0.83 | NPC1 (0.61) | NR1H4EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12940302 | 0.82 | SIRT1 (0.65) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL15861681 | 0.82 | NR3C2 (0.56) | NR1H4EPHX2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106046100-A | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases | 拜耳知识产权有限责任公司 | 2016-10-26 | — | — | CN | claimed |
| CN-102596985-A | 17-hydroxy-17-pentafluoroethyl-estra-4, 9(10) -dien-11-aryl derivatives, method for the production thereof and use thereof for treating diseases | BAYER SCHERING PHARMA AG | 2012-07-18 | — | — | CN | claimed |
| EP-1353926-B1 | MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES | SOD CONSEILS RECH APPLIC (FR) | 2006-03-08 | — | — | EP | claimed |
| JP-2004533456-A | — | — | 2004-11-04 | — | — | JP | claimed |
| EP-1438039-A2 | PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-21 | — | — | EP | claimed |
| US-20040138245-A1 | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-15 | — | — | US | claimed |
| EP-1353926-A1 | MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2003-10-22 | — | — | EP | claimed |
| WO-2002096348-A2 | PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-12-05 | — | — | WO | claimed |
| WO-2002055523-A1 | MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-07-18 | — | — | WO | claimed |
| CN-102596985-B | 17-hydroxy-17-pentafluoroethyl-estra-4, 9(10) -dien-11-aryl derivatives, method for the production thereof and use thereof for treating diseases | 拜耳知识产权有限责任公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-106046100-A | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases | 拜耳知识产权有限责任公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-102596985-A | 17-hydroxy-17-pentafluoroethyl-estra-4, 9(10) -dien-11-aryl derivatives, method for the production thereof and use thereof for treating diseases | BAYER SCHERING PHARMA AG | 2012-07-18 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| WO-2010103381-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES AS TRPM 8 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-09-16 | — | — | WO | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005019162-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORPORATION (KR) | 2005-03-03 | — | — | WO | disclosed |
| EP-1438039-A2 | PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-21 | — | — | EP | disclosed |
| EP-1353926-A1 | MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002096348-A2 | PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002055523-A1 | MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138245-A1 | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | DTYMK, DGKG, DGKZ | NR1H4 2816/4885EPHX2 1630/4885NPC1 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.